Abstract
Dietary habits and incidence of prostate cancer (PCa) are very different in several parts of the world. Among the differences between Eastern and Western diets is the greater intake of soy in the Eastern cultures. This might be one factor contributing to a lower incidence of PCa in Asian men. Many studies using PCa cells and animal studies of chemical carcinogenesis have shown that a wide range of dietary compounds have cancer chemopreventive potential. Therefore, the interest in nutrition-based approaches for prevention and treatment of PCa is increasing. We reviewed all experimental preclinical in vitro and in vivo data as well as clinical trials performed with soy isoflavone genistein for prevention and treatment of PCa. The preclinical data for genistein presented in this review show a remarkable efficacy against PCa cells in vitro with molecular targets ranging from cell cycle regulation to induction of apoptosis. In addition, seemingly well-conducted animal experiments support the belief that genistein might have a clinical activity in human cancer therapy. However, it is difficult to make definite statements or conclusions on clinical efficacy of genistein because of the great variability and differences of the study designs, small patient numbers, short treatment duration and lack of a standardized drug formulation. Although some results from these genistein studies seem encouraging, reliable or long-term data on tumor recurrence, disease progression and survival are unknown. The presented data potentially allow recommending patients the use of genistein as in soy products in a preventive setting. However, at present there is no convincing clinical proof or evidence that genistein might be useful in PCa therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sonn GA, Aronson W, Litwin MS . Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005; 8: 304–310.
Montironi R, Barbisan F, Mazzucchelli R . Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention. Arch Ital Urol Androl 2003; 75: 127–134.
Ferlay J, Bray F, Pisani P, Parkin DM . Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press: Cours Albert-Thomas, Lyon Cedex, France, 2001.
Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 2004; 64: 765–771.
Gonzalez CA . The European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2006; 9: 124–126.
Key TJ, Allen N, Appleby P, Overvad K, Tjonneland A, Miller A et al. Fruits and vegetables and prostate cancer: no association among 1104 cases in a prospective study of 13 0544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004; 109: 119–124.
Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JWJ, Clinton SK . Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003; 95: 1578–1586.
Brossner C, Petritsch K, Fink K, Auprich M, Madersbacher S, Adlercreutz H et al. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology 2004; 64: 707–711.
Chan JM, Gann PH, Giovannucci EL . Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23: 8152–8160.
Etminan M, Takkouche B, Caamano-Isorna F . The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004; 13: 340–345.
Ganry O . Phytoestrogens and prostate cancer risk. Prev Med 2005; 41: 1–6.
Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC . Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767–1776.
Giovannucci E . Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91: 317–331.
Giovannucci E . A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 2002; 227: 852–859.
Gupta S, Ahmad N, Mukhtar H . Prostate cancer chemoprevention by green tea. Semin Urol Oncol 1999; 17: 70–76.
Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D . Dietary flavonoids and cancer risk in the Zutphen elderly study. Nutr Cancer 1994; 22: 175–184.
Imai K, Suga K, Nakachi K . Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 1997; 26: 769–775.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218–220.
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000; 130: 467S–471S.
Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM . Prostate cancer and dietary carotenoids. Am J Epidemiol 2000; 151: 119–123.
Neuhouser ML . Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 2004; 50: 1–7.
Paganini-Hill A, Chao A, Ross RK, Henderson BE . Vitamin A, beta-carotene, and the risk of cancer: a prospective study. J Natl Cancer Inst 1987; 79: 443–448.
Sarkar FH, Li Y . Soy isoflavones and cancer prevention. Cancer Invest 2003; 21: 744–757.
Schulman CC, Ekane S, Zlotta AR . Nutrition and prostate cancer: evidence or suspicion? Urology 2001; 58: 318–334.
Stoner GD, Mukhtar H . Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 1995; 22: 169–180.
Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, Trichopoulou A . Diet and cancer of the prostate: a case–control study in Greece. Int J Cancer 1999; 80: 704–708.
Weinrich SP, Hudson Priest J, Moyad MA, Weinrich MC . Intake of selected nutritional supplements by African-American men. Urology 2004; 64: 1094–1097.
Lippert MC, McClain R, Boyd JC, Theodorescu D . Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999; 86: 2642–2648.
Adlercreutz H, Mazur W . Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95–120.
Heinonen SM, Hoikkala A, Wahala K, Adlercreutz H . Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Biol 2003; 87: 285–299.
Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H . Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 2004; 45: 245–251.
Montironi R, Mazzucchelli R, Marshall JR, Bartels PH . Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol 1999; 52: 793–803.
Evans BA, Griffiths K, Morton MS . Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995; 147: 295–302.
Geller J, Sionit L, Partido C, Li L, Tan X, Youngkin T et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate 1998; 34: 75–79.
Hempstock J, Kavanagh JP, George NJ . Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br J Urol 1998; 82: 560–563.
Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 2004; 49: 200–208.
Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000; 29: 92–102.
Davis JN, Singh B, Bhuiyan M, Sarkar FH . Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998; 32: 123–131.
Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K . Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 1998; 28: 360–363.
Peterson G, Barnes S . Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335–345.
Li Y, Sarkar FH . Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002; 8: 2369–2377.
Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, Uemura H . Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005; 12: 73–80.
Li Y, Sarkar FH . Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002; 132: 3623–3631.
Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R . Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005; 65: 8200–8208.
Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L . Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995; 125: 790S–797S.
Li X, Marani M, Mannucci R, Kinsey B, Andriani F, Nicoletti I et al. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001; 61: 1699–1706.
Davis JN, Kucuk O, Sarkar FH . Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999; 35: 167–174.
Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH . Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934–6942.
Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004; 6: 354–363.
Pollard M, Wolter W . Prevention of spontaneous prostate-related cancer in Lobund–Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000; 45: 101–105.
Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A . Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001; 61: 6777–6782.
Fritz WA, Wang J, Eltoum IE, Lamartiniere CA . Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002; 186: 89–99.
Fritz WA, Eltoum IE, Cotroneo MS, Lamartiniere CA . Genistein alters growth but is not toxic to the rat prostate. J Nutr 2002; 132: 3007–3011.
Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK . Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999; 129: 1628–1635.
Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, Wang H et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 1999; 35: 130–136.
Bylund A, Zhang JX, Bergh A, Damber JE, Widmark A, Johansson A et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000; 42: 304–314.
Bhatia N, Agarwal R . Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001; 46: 98–107.
Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH . Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 2000; 16: 1091–1097.
Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H, Armbrecht HJ . Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 2004; 134: 1207S–1212S.
Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995; 155: 381–386.
Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS . Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90: 1637–1647.
Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002; 11: 1689–1696.
Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003; 77: 875–882.
deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B . Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 2004; 63: 259–263.
Urban D, Irwin W, Kirk M, Markiewicz MA, Myers R, Smith M et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001; 165: 294–300.
Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, Valentine JL et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004; 48: 160–170.
Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002; 75: 126–136.
Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1213–1221.
Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004; 64: 510–515.
Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003; 47: 111–117.
Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59: 141–147.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perabo, F., Von Löw, E., Ellinger, J. et al. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 11, 6–12 (2008). https://doi.org/10.1038/sj.pcan.4501000
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4501000
Keywords
This article is cited by
-
Traversing the Vivid Pharmacological and Nanotechnological Facets of Genistein: Insights into the Past, Present and Future Trends
BioNanoScience (2023)
-
Overexpressing GmCHI1A increases the isoflavone content of transgenic soybean (Glycine max (L.) Merr.) seeds
In Vitro Cellular & Developmental Biology - Plant (2020)
-
Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.f., inhibits prostate cancer bone metastasis
Prostate Cancer and Prostatic Diseases (2017)
-
Influence of testosterone on phase II metabolism and availability of soy isoflavones in male Wistar rats
Archives of Toxicology (2017)
-
Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research
Cancer Causes & Control (2013)